Syngene International
Market cap ₹17,475 Cr
- P/E
- 94.11
- Day range
- ₹430.80 – ₹445.95
- 52-week range
- ₹344.45 – ₹678.95
- Volume
- 5.48 L
- Open
- ₹434.05
- Prev close
- ₹434.35
Latest results · Q2 FY27(consolidated)Revenue ₹833 Cr-8.6%Profit ₹32 Cr-52.0%Margin 3.9%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
SYNGENE in NSE indices and F&O
Research profile
Composite 45 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.1%
- Graham no.
- ₹133.37
- vs Graham
- -69.3%
- ROE ÷ P/B
- 1.8%
- 12-1 mom.
- -38.7%
- Return / vol
- -0.90
- Magic Formula
- #583
- Piotroski
- 2/6
- FCF yield
- 3.1%
Appears in 9 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| Syngene InternationalSYNGENE | ₹17,475 Cr | 94.11 | 3.62 | 6.6% | 10.0% | 18.0% | 0.10 | -8.6% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 21h agoHeadlines about Syngene International from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 66.0
- Price / Book
- 3.62
- ROE (FY26)
- 6.6%
- ROCE (latest year)
- 10%
- Dividend yield
- 0.29%
Moving averages (NSE)
- 20-day
- ₹410.23
- Price above
- 50-day
- ₹389.92
- Price above
- 200-day
- ₹419.41
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- DII
- FII
- Public
- Others
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the bonus of 11 Jun 2019: earlier bars are per pre-bonus share.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 854 | 917 | 790 | 891 | 944 | 1,018 | 874 | 911 | 917 | 1,036 | 736 | 833 |
| YoY Sales growth | — | -8 | -2 | -2 | — | — | — | — | -3 | — | -16 | -9 |
| Expenses | 622 | 600 | 620 | 646 | 660 | 674 | 668 | 711 | 708 | 733 | 645 | 685 |
| Operating Profit | 232 | 317 | 170 | 245 | 284 | 344 | 206 | 200 | 209 | 303 | 91 | 147 |
| OPM % | 27% | 35% | 22% | 27% | 30% | 34% | 24% | 22% | 23% | 29% | 12% | 18% |
| Other Income | 26 | 16 | 50 | 16 | 18 | 19 | 18 | 15 | -55 | 16 | 12 | 21 |
| Interest | 11 | 13 | 12 | 13 | 12 | 16 | 12 | 13 | 12 | 12 | 10 | 10 |
| Depreciation | 108 | 111 | 107 | 111 | 109 | 106 | 111 | 116 | 114 | 112 | 112 | 112 |
| Profit before tax | 138 | 209 | 101 | 137 | 181 | 240 | 101 | 85 | 28 | 196 | -19 | 47 |
| Tax % | 19% | 10% | 25% | 23% | 27% | 24% | 14% | 21% | 47% | 25% | -53% | 31% |
| Net Profit | 112 | 189 | 76 | 106 | 131 | 183 | 87 | 67 | 15 | 148 | -9 | 32 |
| EPS in Rs | ₹2.77 | ₹4.69 | ₹1.88 | ₹2.64 | ₹3.26 | ₹4.55 | ₹2.15 | ₹1.67 | ₹0.37 | ₹3.67 | ₹-0.22 | ₹0.80 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-29 days since Mar 2021
+15 days since Mar 2021
-29 days since Mar 2021
+15 days since Mar 2021
-2 days since Mar 2021
Strengths, risks & growth
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 3.61 times its book value
- The company has delivered a poor sales growth of 11.4% over past five years.
- Company has a low return on equity of 10.2% over last 3 years.
- Dividend payout has been low at 12.0% of profits over last 3 years
Compounded Sales Growth
- 10 Years
- —
- 5 Years
- +11%
- 3 Years
- +5%
- TTM
- -6%
Compounded Profit Growth
- 10 Years
- —
- 5 Years
- 0%
- 3 Years
- -8%
- TTM
- -43%
Stock Price CAGR
- 10 Years
- +5%
- 5 Years
- -6%
- 3 Years
- -16%
- 1 Year
- -33%
Return on Equity
- 10 Years
- —
- 5 Years
- +11%
- 3 Years
- +10%
- Last Year
- +8%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 52.68% | 52.68% | 52.59% | 52.59% | 0.00 pp |
| FII | 14.96% | 13.91% | 11.82% | 10.13% | -1.69 pp |
| DII | 25.83% | 26.44% | 28.01% | 29.31% | +1.30 pp |
| Public | 6.22% | 6.69% | 7.15% | 7.55% | +0.40 pp |
| Others | 0.29% | 0.29% | 0.43% | 0.41% | -0.02 pp |
Filed with NSE for Sept 2026: promoters 52.59%, public 47.00%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 27.21% (+1.32 pp)- Promoters52.8%
- Foreign institutions10.2%
- Mutual funds27.2%
- Insurance2.1%
- Other domestic institutions0.1%
- Retail5.0%
- Others2.6%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Nippon India Small Cap Fund | 3.29% | 0.75% | +0.14 pp |
| ICICI Pru Multi Cap Fund | 1.83% | 1.78% | +0.43 pp |
| Nippon India Multi Cap Fund | 1.56% | 0.51% | +0.05 pp |
| ICICI Pru Healthcare Fund | 1.53% | 3.76% | +0.50 pp |
| Nippon India Focused Fund | 1.40% | 3.03% | +0.32 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 292 daily sessions to 18 Nov 2026.
Risk
- Volatility (1Y)
- 34.6%
- Downside volatility
- 33.6%
- Worst 5% of days
- 3.3%
- Average of that tail
- 5.1%
- Max drawdown (1Y)
- 48.4%
- Below its peak
- 35.2%
Against the market
- Beta vs Nifty 50
- 0.71
- Correlation
- 0.28
- Relative strength (3M)
- +4.0%
- ATR (14)
- 3.4%
Return
- Return 1M
- +12.6%
- Return 3M
- +7.9%
- Return 6M
- -6.8%
- Return 1Y
- -31.0%
- vs 200-day average
- +3.7%
Momentum
- RSI (14)
- 62.2
- MACD histogram
- 2.28
- Stochastic %K
- 69.5
- ADX (14)
- 39.1
- +DI / −DI
- 30.5 / 11.5
- Money flow index
- 64.7
Participation
- Delivery (20d avg)
- 48.9%
- vs its 60-day baseline
- -2.7 pts
- Volume vs 20-day
- -0.3σ
- Close vs day's VWAP
- -0.7%
- 52-week position
- 27 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
2 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — passed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹547 Cr
- FCF yield
- 3.1%
- Cash conversion
- 2.89
- Accruals ratio
- -0.085
- Net debt
- ₹388 Cr
- Net debt / equity
- 0.08
- EV / sales
- 5.07
- Capex intensity
- 9.8%
- Revenue CAGR
- -12.5%
- Profit CAGR
- -68.6%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- dividend₹1.25
Dividend - Rs 1.25 Per Share
25 Jun 2026ex-date - dividend₹1.25
Dividend - Rs 1.25 Per Share
27 Jun 2025ex-date - dividend₹1.25
Dividend - Rs 1.25 Per Share
28 Jun 2024ex-date - dividend₹0.50
Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.75 Per Share
30 Jun 2023ex-date - dividend₹0.50
Dividend - Rs 0.50 Per Share/Special Dividend - Rs 0.50 Per Share
30 Jun 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
13 Jul 2021ex-date - dividend₹0.50
Dividend - Rs 0.50 Per Share
16 Jul 2019ex-date - bonusNot available — not reported in this filing
Bonus 1:1
11 Jun 2019ex-date - dividendNot available — not reported in this filing
Dividend Re - Re 1 Per Share
17 Jul 2018ex-date - dividend₹1.00
Dividend - Rs 1/- Per Share
20 Jul 2017ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 1/- Per Share (Purpose Revised)
17 Mar 2016ex-date
Company announcements
Intimation of Conference Call for Analysts and Investors
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulation, 2018.
Syngene International Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Un-Audited Standalone ....
Intimation of Closure of Trading Window
Intimation of cancellation of meeting with Analyst/Institutional Investors
Resignation of Mr. Pramuch Goel as Head Corporate Affairs & Communications and a member of Executive Committee (Senior Management Personnel) of the Company w.e.f. the close of business ....
Intimation of Schedule of Meeting with Analyst/Institutional Investor
Intimation of Schedule of Meeting with Analyst/Institutional Investor
Intimation of Schedule of Meeting with Analyst/Institutional Investor
Communication regarding remittance of final dividend for the FY 2025-26
Grant of Performance Share Units under Syngene Long Term Incentive Performance Share Plan (PSP) 2023 ("Plan")
Intimation of Schedule of Investor/Analyst Meeting with Goldman Sachs Asia Leaders Conference 2026
Intimation of investment in Ampin C&I Power Twelve Private Limited
Intimation of Investor call schedule with Entrust Family Office
Intimation of Schedule of Meeting with Analyst/Institutional Investor on August 13, 2026 and August 14, 2026.
Filed with BSE (scrip 539268); the last 45 days. Documents open at bseindia.com.
Documents
Annual reports
Earnings calls
- Oct 2026TranscriptSlidesRecording
- Jul 2026TranscriptSlidesRecording
- Apr 2026TranscriptSlidesRecording
- Jan 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
- Sep 2025Slides
Credit ratings
- Rating update · 11 Sep from crisil
- Rating update · 20 Nov 2025 from icra
- Rating update · 30 Oct 2025 from icra
- Rating update · 17 Jun 2025 from crisil
- Rating update · 25 Nov 2024 from crisil
- Rating update · 30 Aug 2024 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Syngene International: common questions
Answered from the figures on this page.